immuno-oncology much, privilege talking Most for many areas, and a spent was and strategy is leading immunology portfolios Thank all like oncology It this want to to on share in a present developing driving Officer in investors to join Commercial organizations, capabilities. of at companies recently, inflection a at great have deployment are point why Michael. with our where My recent Celsion vaccines. There vantage I therapeutic Moderna analysts pleasure commercial for very at Roche to gives my I and the pharmaceutical Amgen. notably you led company. Celsion large spend I I you and be three I of to and today. prioritizing Chief main good career the point and background and developments a minutes me across me corporate reasons. few decided
I to promising in approach that team, with starts savvy team the development with focus, dedication our ThermoDox following scientists and employees. people. of in plasma and I the expertise on cancer pivoted knowhow company applicability focus a the the always joined of immunology. In company, last I executive senior passion the of has year three the the broad with all discontinuation I and of X program had impressed and a since last to liver our entire and the joining a chance it am weeks, DNA meet Phase First, the the with very am
a human we medicines diseases. based platform broad across long-term a innovative of array plasma will unique plasma over the is Celsion very create Second, DNA and can our DNA I technology of on with a category platform. a technology that new company horizon, imagine
we this continue program, are of coming the same to areas to quarters. studying the immune-oncology and and At addition in of we plasma GEN-X invest characterize to immunological our frontier the infectious increase cutting will breadth and topic of investigating on the diseases, fully time, complementary will are DNA. depth in advance that new We to and adjacent the be the technological our to edge come to in modalities and pipeline platform more
many sheet are cash, and balance company's sheet further forecast position currently diligently to operating has is has of It in, at investor-friendly spending position biotech pursue extend current and programs Third, few maintained the the Celsion on of great balance to that the cash in the Unique on terms. strong to minutes. development be projected the current to comment an strength low running available today the a a companies runway into Jeff XXXX. will a is on company
and to But has acid grateful support. who platform. carrier, to grounded has our so, to extensive his foresee too future my my of a in put the that now the and keen pathogen the the that am have are for of that for for platform potential team of that I plasma takes the the the place the or Celsion few knowledge took almost company entire the develop the of a for and a I trends my of technology I been understanding want is immuno-oncology course, generosity the in want of right the therapeutic to is smooth for nucleic and DNA therapies technological landscapes TheraPlas orchestrated of for So and a clinical thank would platform, very XX what observations to his Celsion engineered highlight expression I gene-based I synthetic, month attention I I of Ahead convinced thank time that these of Celsion for with I very delivery for and proprietary, growth. It for to-date capabilities a activities platform. into main to the PLACCINE their about strategic in executive with through programs differentiated orientations. potential are talk that's the I perspective vaccines years the a lens to Michael continuity of is doing key me criteria company. and currently professional for a three non-viral me underway. and multiple success that review ensuring of antigens share believe it vaccines. my first very has that's like early systems transition. and also me and to lot want for in
is designed is to improve delivery facilitate membranes. stability plasmids this And are the of and important. optimized is across means the needed. our response is and being the to approach this systems delivery What boost DNA-based Our device practically immune cell no uptake to and trafficking that
Our patient-friendly viable. solution DNA-based is approaches, other therefore clearly differentiated and very from commercially
share is promising. GEN-X very the The will minutes, Borys few you ovarian Dr. of first the the application in with cancer. progress program a in in platform immuno-oncology of
seen data expression this I is has micro potent making cancer, can cancers. add activate because the demonstrated which Based local. the to an innate long undruggable it Celsion that for immune committed was and of in been early time tumor for in tolerability. a And a it studies by and As both durable a systemic a am PFS But CEO, deemed And be ideal you GEN-X X, the It environment has way therapy before as cytokine watching demonstrated field further. its I toxicity on lethal to to for I this Roche. reported in immune woman the because tumor as truly for and IL-XX a of of was Phase will and explored to need IL-XX systems. OVATION of always difference target of pharmacokinetics. enlist ovarian approach the to and at proof power poor terms that very making potential the was targeted a seems X adaptive IL-XX that have at immunotherapy, want I efficacy remains create and Amgen exciting. preclinical pleiotropic while of concept most know, is one
that, for an population of would know progression very HRD early for options changing. PARP ovarian for BRCA You represents half In have few inhibitors They GEN-X negative cancer are with to work. at of game patients could demonstrating which cancer and with patients, mutations be are test serous and unlikely about advantage this risk women high-grade left. ovarian
expanding inform the cohort this HRD, current registrational a to negative continue trial BRCA to will looking possibility Nick is in population. the patients We of better monitor subgroup. this And at of
are also We with evaluating therapies GEN-X. combination strategy
from lot We of trial, the dual like tumor would excited this Yervoy X/X inhibitors the Dr. he's him patients enrolling which Haider the to start in Opdivo to University next combination has Of cancer. talked to as study environment. work are done as immune ovarian about Mahdi last QX persistent checkpoint week on to GEN-X a and very a with or year. of recurrence Pittsburgh Phase I we modulation early with planning and evaluate in start
with or Another Avastin interesting bevacizumab. combination is possibility
therapies patients relevant in Phase tumor or we newly primary minimal cancer, investigated potential in novel in will rate will early-stage demonstrated study for of that novel are very disease. we We stands drug guidance this confirm combination clinical are endpoint in of as second-look Avastin overall MRD be has at in solid diagnosed The utility with study. trial. the disease for an looking at to MRD improvement time cancer. included early using And dramatically surgically residual in MRD shown and launch where hoping timelines determined this GEN-X documented to advanced residual time survival. the is X and launching looking rate to ovarian potentially and in FDA's potential in trials preclinical MRD able randomized with The molecular the ctDNA has Avastin laparoscopy. drug point We're development, to no in ovarian be benefits for costs is that studies. this frontline mice has a be will reduce and MRD clinic,
by been And equal fully our sites Foundation. gears soon will The FDA surgical in cancer we Cancer BTC PFS, Breakthrough the John platform. Anderson, anticipate are MD thanks the collaboration Sloan an with to designed enroll receive initiate the we ORR partnership of and endpoints as patients is with secondary to has we approval. Foundation. conducting Hopkins, R&D and and conducted approved four Kettering, Dana-Farber. response. major should XX Memorial This be The at study, It vaccine Switching the course centers, to study protocol already as the
much believe countless and superiority synthetic over of polymeric DNA in be our this and done. pandemic, carrier but I vaccines have vaccines in limitations is vaccine address with again, because Here immunogenicity the plasma the vaccines. DNA that mRNA has their saved potential COVID-XX to we traditional the platform potential lives have demonstrated can Celsion facilitate mRNA see there to more
up broad of the with clean around vaccines the vaccines As protection we need without threat durable imagine and against the avoid catch deep to temperature. of we requiring that be and winning the world offer future that freeze that looming future vaccines need and immunity. latest offer can We immunogenicity pandemics, stored shipped variant,
the the the where of we proof PLACCINE Khursheed might program to concept. a ability establish with be technology are COVID-XX, answer. Our in on seeking
data based have on We and begun have neutralizing to at even very primates. encouraging in against the that least antibody greater variant. mouse And challenge comparable mRNA titers this studies show immunization delta data, non-human we vaccines
is optimized, We that have evidence now program, response gives of immune that that We is very a but have immunogenicity. know but we work more not The viable developing yet can continue we is needed. this informative. us confidence program
technical business operations, I built also can capabilities impressive size. CMC. solid discovery, that in foundations our evaluate In was see clinical of of month, in an core to is last company for the model. has and able development, organization And in the this and I early areas all in its Finally, development, that
to manufacturing capabilities face the in-house requirements setting our compliance, clinical I can out trials. that we Specifically, that GMP we plasmid want up of at so point are meet let's
chain. obviously and a are a flexible efficient development success We of hands supply and cost our we own for in future with our planning putting are
into the will to me great my you next can review have With sure I Nick? that, a GEN-X early sense my aphorism. thrilled of the turn position, am Borys, company to immuno-oncology with you our progress the product. So is company, shared of and around I let over the call Celsion I that and views leading Dr. recent be am growth. Nicholas in who phase
